© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
AAAAI
AAAAI / WAO Joint Congress as we explore the critical intersection of climate change and allergic diseases and explore their profound global implications on health. You will learn from, and connect with, renowned experts from across the globe, discover cutting-edge research and make connections that will last a lifetime. Together, we'll turn ideas into action, connect with purpose and create lasting impact.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
Investigators concluded that dupilumab reduced exacerbation rates, improved lung function, and decreased systemic corticosteroid use in patients with COPD driven by type 2 inflammation.
AAAAI 2025: Data from the ANCHOR-1 and ANCHOR-2 phase 3 trials show improvements in nasal polyp size and obstruction for depemokimab with twice-yearly dosing vs placebo.
Safety findings from the phase 3 OUtMATCH trial were notable, including no adverse events for omlizumab vs 30.5% for OIT and epinephrine use for 0% vs 37.3%, respectively.
Participants (aged 6 to 17 years) receiving neffy vs standard treatments had fewer skin, gastrointestinal, and respiratory symptoms at 15, 5, and 5 minutes, respectively.
AAAAI 2025: Dupilumab was associated with a 56.9% reduction in IgE levels at 12 months and of 73.5% at 24 months, according to results presented at AAAAI 2025.
AAAAI 2025: Phase 2 study results showed POIT with home-measured peanut products was not only highly effective but also posed few risks.